Browse a selection of key resources and publications about our pipeline.

Engaging Natural Killer Cells for Cancer Therapy via NKG2D, CD16A and Other Receptors (2023 mAbs)

A Phase 1 Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Intratumoral CLN-617 (IL2/IL12 Fusion Protein) Combined with Pembrolizumab in Patients with Advanced Solid Tumors (2023 TiP SITC)

CLN-619, a Clinical-Stage MICA/B-Specific IgG1 Antibody, Restores the MICA/MICB-NKG2D Axis to Promote NK-Mediated Tumor Cell Lysis (2022 AACR)

CLN-619, a Clinical-Stage MICA/B-Specific IgG1 Antibody Which Restores the MICA/B-NKG2D Axis Requires Fc Function for Potent Anti-Tumor Activity (2022 SITC)

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (2022 ESMO)

A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (2022 ASCO)

Phase 1/2a Study of CLN-081 in NSCLC Patients with EGFR Exon 20 Insertion (ex20ins) Mutations (2022 ASCO)

CLN-617 is a First-in-Class Fusion Protein that Retains IL-2 and IL-12 in the Injected Tumor and Potently Triggers Systemic Anti-Tumor Immunity (2023 AACR)

CLN-049 is a Bispecific T Cell-Engaging, IgG-Like Antibody Targeting FLT3 on AML Cells (2022 AACR)

Preclinical Characterization of a Next-Generation CD19/CD3-Bispecific T Cell Engaging Antibody Construct CLN-978 With Long Serum Half-Life and Superior Potency Against Target Cells Expressing Very Low Levels of CD19 (2022 AACR)